EPCAM and hepatocellular carcinoma: Taken together, these findings suggest that DC101 not only simply inhibited angiogenesis but also may have the potential of exerting antitumor effects by reducing AFP-positive/EpCAM-positive HCC CSCs and inhibiting the cell–cell interactions between AFP-positive/EpCAM-positive HCC CSCs and ECs.